16 terminated. 16 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Terminated 16 |
| Phase 2 | 3 | Terminated 3 |
Follow Chromosome Disorders: new trials by email Literature Review of Chromosome Disorders trials Research Report on Chromosome Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial Placebo, ARD-101 - Hyperphagia, Prader-Willi Syndrome | Phase 3 | Terminated | Aardvark Therapeutics, Inc. | 68 | 2024-12-20 | 2026-06-30 |
| The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial ARD-101 - Hyperphagia, Prader-Willi Syndrome | Phase 3 | Terminated | Aardvark Therapeutics, Inc. | 19 | 2024-07-23 | 2026-06-30 |
| LIFE-DSR-Biomarker Sub-study of Biomarkers in Down Syndrome Related Alzheimer's Disease (DS-AD) [18F]MK-6240 - Down Syndrome | Phase 3 | Terminated | LuMind IDSC Foundation | 5 | 2023-06-27 | 2025-03-06 |
| A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome RAD011, Placebo - Prader-Willi Syndrome | Phase 2 / Phase 3 | Terminated | Radius Pharmaceuticals, Inc. | 4 | 2022-04-13 | 2023-10-19 |
| Effects of Livoletide (AZP-531) on Food-related Behaviors in Patients With Prader-Willi Syndrome Livoletide, Placebo - Prader-Willi Syndrome, Hyperphagia | Phase 2 / Phase 3 | Terminated | Millendo Therapeutics SAS | 158 | 2019-03-25 | 2021-02-17 |
| An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome OV101 - Angelman Syndrome | Phase 3 | Terminated | Healx AI | 141 | 2019-01-31 | 2025-07-18 |
| Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome ZGN-440 for Injectable Suspension, ZGN-440 Placebo for Injectable Suspension - Prader-Willi Syndrome, Obesity | Phase 3 | Terminated | Zafgen, Inc. | 108 | 2014-09-01 | 2017-01-26 |
| Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 Weeks Topiramate, Placebo Comparator - Prader-Willi Syndrome | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 69 | 2012-12-01 | 2018-04-11 |
| Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label) AFQ056 - Fragile X Syndrome | Phase 2 / Phase 3 | Terminated | Novartis Pharmaceuticals | 119 | 2011-11-01 | 2016-03-24 |
| An Open Label Extension Study in Subjects With Fragile X Syndrome arbaclofen - Fragile X Syndrome | Phase 3 | Terminated | Seaside Therapeutics, Inc. | 357 | 2011-11-01 | 2013-07-31 |
| Preimplantation Genetic Diagnosis (PGD) by Array Comparative Genome Hybridization (CGH) and Blastocyst Biopsy Preimplantation Genetic Diagnosis - Infertility, Miscarriage | Phase 3 | Terminated | Reprogenetics | 120 | 2011-04-01 | 2012-05-30 |
| Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17 Aricept (donepezil hydrochloride), Placebo - Down Syndrome, Cognitive Dysfunction | Phase 3 | Terminated | Eisai Inc. | 8 | 2008-09-01 | 2018-04-23 |
| Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10 Aricept (Donepezil hydrochloride), Placebo - Down Syndrome, Cognitive Dysfunction | Phase 3 | Terminated | Eisai Inc. | 9 | 2008-09-01 | 2020-01-28 |
| Effect of Rimonabant on Weight Gain and Body Composition in Adults With Prader Willi Syndrome rimonabant, placebo - Prader-willi Syndrome | Phase 3 | Terminated | Weill Medical College of Cornell University | 10 | 2007-08-01 | 2023-03-20 |
| Effects of PTH Replacement on Bone in Hypoparathyroidism PTH 1-34 - Hypoparathyroidism, DiGeorge Syndrome | Phase 3 | Terminated | National Institute of Dental and Craniofacial Research (NIDCR) | 46 | 2006-10-30 | 2019-08-28 |
| Prader-Willi Syndrome and Appetite Sandostatin LAR - Hyperphagia, Prader-Willi Syndrome | Phase 3 | Terminated | University of British Columbia | 10 | 2004-08-01 | 2007-10-31 |
Prader-Willi Syndrome (8) · Hyperphagia (5) · Down Syndrome (4) · Cognitive Dysfunction (2) · Fragile X Syndrome (2) · Obesity (2) · Abortion, Spontaneous (1) · Angelman Syndrome (1) · Body Weight (1) · DiGeorge Syndrome (1) · Feeding and Eating Disorders (1) · Genetic Diseases, Inborn (1) · Hypoparathyroidism (1) · Impulsive Behavior (1) · Infertility (1)
Congenital Abnormalities (16) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (16) · Genetic Diseases, Inborn (15) · Nervous System Diseases (15) · Abnormalities, Multiple (14) · Intellectual Disability (14) · Neurobehavioral Manifestations (14) · Neurologic Manifestations (14) · Imprinting Disorders (9) · Nutrition Disorders (8) · Nutritional and Metabolic Diseases (8) · Overnutrition (8) · Overweight (8) · Pathological Conditions, Signs and Symptoms (7)
Donepezil (2) · CKD732 (1) · Parathyroid Hormone (1) · Rimonabant (1) · Topiramate (1) · arbaclofen placarbil (1) · cyclic des-acyl ghrelin (6-13) (1) · gaboxadol (1) · mavoglurant (1)
Aardvark Therapeutics, Inc. (2) · Eisai Inc. (2) · Assistance Publique - Hôpitaux de Paris (1) · Healx AI (1) · LuMind IDSC Foundation (1) · Millendo Therapeutics SAS (1) · National Institute of Dental and Craniofacial Research (NIDCR) (1) · Novartis Pharmaceuticals (1) · Radius Pharmaceuticals, Inc. (1) · Reprogenetics (1) · Seaside Therapeutics, Inc. (1) · University of British Columbia (1) · Weill Medical College of Cornell University (1) · Zafgen, Inc. (1)
United States (13) · Australia (4) · United Kingdom (4) · Canada (3) · France (3) · Belgium (2) · Israel (2) · Italy (2) · Netherlands (2) · South Korea (2) · Spain (2) · Denmark (1) · Germany (1) · Peru (1) · Sweden (1)
Thomas McRae, MD (2) · Dennis Kim, MD (1) · Jean-Pierre Chanoine, MD (1) · Moris Angulo, MD (1) · Paul Wang, M.D. (1) · Rachel I Gafni, M.D. (1) · Roja Motaghedi, MD (1) · Santiago Munne, PhD (1)